Last checked at 23 Jan 2019 11:25
REDX PHARMA PLC
("Redx" or "the Company")
Results of Annual General Meeting
Alderley Park, 23 January 2019 Redx (AIM: REDX), the drug discovery and development company focused on cancer and fibrosis, announces that all resolutions at the Group's Annual General Meeting, held today, were duly passed.
For further information, please contact:
Redx Pharma Plc | T: +44 1625 469 920 |
Lisa Anson, Chief Executive Officer |
|
Dominic Jackson, Chief Financial Officer |
|
|
|
Cantor Fitzgerald Europe (Nominated Advisor & Joint Broker) | T: +44 20 7894 7000 |
Phil Davies |
|
|
|
WG Partners LLP (Joint Broker) | T: +44 20 3705 9330 |
Claes Spång/ Chris Lee/ David Wilson |
|
|
|
FTI Consulting | T: +44 20 3727 1000 |
Simon Conway/Stephanie Cuthbert |
|
About Redx Pharma Plc
Redx is a UK based biotechnology company whose shares are traded on AIM (AIM:REDX). Redx's vision is to become a leading biotech focused on the development of novel precision medicines that have the potential to transform treatment in oncology and fibrotic diseases.
If you would like to sign up to regular alerts from Redx Pharma, please follow this link https://www.redxpharma.com/investors/email-alerts/